{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:32Z","timestamp":1786987052951,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clml.2026.02.004","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:35:52Z","timestamp":1771054552000},"page":"297-308.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor\u2013Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7696-4752","authenticated-orcid":false,"given":"Nicolaas P.M.","family":"Schaap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9593-8947","authenticated-orcid":false,"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-3113","authenticated-orcid":false,"given":"Juan Carlos","family":"Hernandez-Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Devos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethan","family":"Psaila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal P.","family":"McLornan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Strouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3200-6234","authenticated-orcid":false,"given":"Jessica","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6068-2326","authenticated-orcid":false,"given":"Dwaipayan","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.02.004_bib0001","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.02.004_bib0002","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2026.02.004_bib0003","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.02.004_bib0004","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.02.004_bib0005","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1038\/bcj.2011.36","article-title":"How I treat splenomegaly in myelofibrosis","volume":"1","author":"Cervantes","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.02.004_bib0006","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the Mayo Clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2026.02.004_bib0007","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/HS9.0000000000000001","article-title":"Myelofibrosis-related anemia: current and emerging therapeutic strategies","volume":"1","author":"Naymagon","year":"2017","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2026.02.004_bib0008","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.02.004_bib0009","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.004_bib0010","unstructured":"Omjjara (momelotinib). Summary of product characteristics. GSK; 2025. Accessed: December 1, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/omjjara-epar-product-information_en.pdf."},{"key":"10.1016\/j.clml.2026.02.004_bib0011","unstructured":"Ojjaara (momelotinib). Prescribing information. GSK; 2025. Accessed: December 1, 2025. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Ojjaara\/pdf\/OJJAARA-PI-PIL.PDF."},{"key":"10.1016\/j.clml.2026.02.004_bib0012","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.004_bib0013","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","article-title":"ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial","volume":"4","author":"Oh","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.02.004_bib0014","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.02.004_bib0015","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.02.004_bib0016","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.02.004_bib0017","unstructured":"Jakafi (ruxolitinib). Prescribing information. Incyte Corporation; 2023. Accessed: December 1, 2025. https:\/\/www.jakafi.com\/jakafi-prescribing-information."},{"key":"10.1016\/j.clml.2026.02.004_bib0018","unstructured":"Jakavi (ruxolitinib). Summary of product characteristics. Novartis; 2025. Accessed: December 1, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jakavi-epar-product-information_en.pdf."},{"key":"10.1016\/j.clml.2026.02.004_bib0019","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/10428194.2020.1845334","article-title":"Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study","volume":"62","author":"Gupta","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.02.004_bib0020","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/cncr.34722","article-title":"Ruxolitinib in cytopenic myelofibrosis: response, toxicity, drug discontinuation, and outcome","volume":"129","author":"Palandri","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.02.004_bib0021","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2026.02.004_bib0022","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.02.004_bib0023","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood.2024024220","article-title":"Identifying disease-modifying potential in myelofibrosis clinical trials","volume":"144","author":"Ross","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.004_bib0024","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.02.004_bib0025","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1038\/s41375-022-01637-7","article-title":"Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis","volume":"36","author":"Mesa","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.02.004_bib0026","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/ejh.14321","article-title":"Pacritinib response is associated with overall survival in myelofibrosis: PERSIST-2 landmark analysis of survival","volume":"114","author":"Ajufo","year":"2025","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2026.02.004_bib0027","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.004_bib0028","series-title":"Leuk Lymphoma","first-page":"1","article-title":"Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival","author":"Kuykendall","year":"2026"},{"key":"10.1016\/j.clml.2026.02.004_bib0029","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/10428194.2024.2328800","article-title":"Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial","volume":"65","author":"Gupta","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.02.004_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70062","article-title":"Revised \"iRR6\" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib","volume":"131","author":"Palandri","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.02.004_bib0031","doi-asserted-by":"crossref","first-page":"e963","DOI":"10.1097\/HS9.0000000000000963","article-title":"Momelotinib in myelofibrosis patients with thrombocytopenia: post hoc analysis from three randomized phase 3 trials","volume":"7","author":"Kiladjian","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2026.02.004_bib0032","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2010.031831","article-title":"Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS","volume":"96","author":"Elena","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.02.004_bib0033","series-title":"Poster presented at the 65th Annual ASH Annual Meeting","article-title":"Red blood cell transfusion independence status is an independent predictor of survival: a post hoc time-dependent analysis of the phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials","author":"Gupta","year":"2023"},{"key":"10.1016\/j.clml.2026.02.004_bib0034","series-title":"Poster presented at the EHA2024 Congress","article-title":"The impact of new or worsening anemia on clinical outcomes in 2233 patients with myelofibrosis treated with ruxolitinib: results from the expanded-access JUMP study","author":"Al-Ali","year":"2024"},{"key":"10.1016\/j.clml.2026.02.004_bib0035","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/cncr.35156","article-title":"Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy","volume":"130","author":"Palandri","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.02.004_bib0036","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1007\/s12325-024-02928-4","article-title":"Momelotinib versus continued ruxolitinib or best available therapy in JAK inhibitor-experienced patients with myelofibrosis and anemia: subgroup analysis of SIMPLIFY-2","volume":"41","author":"Harrison","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2026.02.004_bib0037","series-title":"Poster presented at the 64th Annual ASH Annual Meeting, New Orleans, LA, December 10-13","article-title":"Transfusion independence response as a potential surrogate for overall survival in JAKi-experienced patients with myelofibrosis from MOMENTUM","author":"Verstovsek","year":"2022"},{"key":"10.1016\/j.clml.2026.02.004_bib0038","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","article-title":"Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients","volume":"32","author":"Nicolosi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.02.004_bib0039","series-title":"Poster presented at the 67th ASH Annual Meeting","article-title":"Prognostic impact of persistent and treatment-emergent cytopenia in 879 myelofibrosis patients treated with ruxolitinib: the \u201cRUX-MF\u201d study","author":"Palandri","year":"2025"},{"key":"10.1016\/j.clml.2026.02.004_bib0040","series-title":"Poster presented at the EHA2025 Congress, Milan, Italy, June 12-15","article-title":"Survival impact and kinetics of hemoglobin improvement with momelotinib in patients with myelofibrosis and moderate to severe anemia: post hoc analyses of SIMPLIFY-1 and MOMENTUM","author":"Palandri","year":"2025"},{"key":"10.1016\/j.clml.2026.02.004_bib0041","doi-asserted-by":"crossref","first-page":"10612","DOI":"10.1002\/cam4.5799","article-title":"Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies","volume":"12","author":"Mesa","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2026.02.004_bib0042","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jval.2024.01.014","article-title":"Meaningful symptomatic change in patients with myelofibrosis from the SIMPLIFY studies","volume":"27","author":"Hudgens","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2026.02.004_bib0043","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41591-025-03572-3","article-title":"Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial","volume":"31","author":"Rampal","year":"2025","journal-title":"Nat Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600039X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600039X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:37:34Z","timestamp":1778067454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502600039X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S215226502600039X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.02.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor\u2013Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}